Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C8H12N2.ClH |
| Molecular Weight | 172.655 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC(NN)C1=CC=CC=C1
InChI
InChIKey=FLMNJZPWUCHXNJ-UHFFFAOYSA-N
InChI=1S/C8H12N2.ClH/c1-7(10-9)8-5-3-2-4-6-8;/h2-7,10H,9H2,1H3;1H
Mebanazine is an inhibitor of monoamine oxidase. It was introduced in the 1960s for the treatment of depression and was marketed under trade name Actomol. The drug was withdrawn from the market due to hepatotoxicity. In addition to its antidepressant effect, the drug was found to possess an anorexic action and in animal models, it potentiated the hypoglycemic response to insulin and delayed the recovery of blood glucose levels to normal.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Contribution of sleep research to the development of new antidepressants. | 2005 |
|
| A preliminary trial of mebanazine in depressive states. | 1965-11-01 |
|
| A controlled trial of mebanazine ('Actomol') in depression. | 1965-11 |
|
| Clinical trial of mebanazine--a new monoamine oxidase inhibitor. | 1965-09 |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
34527
Created by
admin on Mon Mar 31 22:53:55 GMT 2025 , Edited by admin on Mon Mar 31 22:53:55 GMT 2025
|
PRIMARY | |||
|
29248-55-3
Created by
admin on Mon Mar 31 22:53:55 GMT 2025 , Edited by admin on Mon Mar 31 22:53:55 GMT 2025
|
PRIMARY | |||
|
2M3FU59FTM
Created by
admin on Mon Mar 31 22:53:55 GMT 2025 , Edited by admin on Mon Mar 31 22:53:55 GMT 2025
|
PRIMARY | |||
|
DTXSID90951850
Created by
admin on Mon Mar 31 22:53:55 GMT 2025 , Edited by admin on Mon Mar 31 22:53:55 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
